Apatinib is a small molecule tyrosine kinase inhibitor that highly selectively binds to and inhibits vascular endothelial growth factor receptor 2. At present, targeted therapy is seldomly applied in the treatment of salivary gland tumors. This article reported one case of salivary gland malignancy in Renmin Hospital of Wuhan University given apatinib after diagnosis. The patient got CT scan again after having taken apatinib more than 1 month and the result suggested that compared with before treatment, the primary lesion and metastasis significantly reduced, which proved that the drug was effective in the case. At the same time in the process of treatment, we gave positive treatment for adverse effects to ensure the efficacy of drugs and improve the safety of medication. The diagnosis and treatment of the patient in this case provides a new thought and guidance for advanced malignant salivary gland tumors.